Are PCSK9 Inhibitors Cost Effective?

Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel

(2017) Brian A. Ference et al.   EUROPEAN HEART JOURNAL

Updated Cost-effectiveness Analysis of PCSK9 Inhibitors Based on the Results of the FOURIER Trial

(2017) Dhruv S. Kazi et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease

(2017) Marc S. Sabatine et al.   NEW ENGLAND JOURNAL OF MEDICINE

A Highly Durable RNAi Therapeutic Inhibitor of PCSK9

(2017) Kevin Fitzgerald et al.   NEW ENGLAND JOURNAL OF MEDICINE

Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients

(2017) Paul M Ridker et al.   NEW ENGLAND JOURNAL OF MEDICINE

Evolocumab for Treating Primary Hypercholesterolaemia and Mixed Dyslipidaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

(2017) Christopher Carroll et al.   PHARMACOECONOMICS

Evolocumab “must become cheaper” to be cost effective in enhancing benefits of statins

(2017) Nigel Hawkes   BMJ-British Medical Journal

Evolocumab “must become cheaper” to be cost effective in enhancing benefits of statins

(2017) Nigel Hawkes   BMJ-British Medical Journal

Cost-effectiveness of Evolocumab Therapy for Reducing Cardiovascular Events in Patients With Atherosclerotic Cardiovascular Disease

(2017) Gregg C. Fonarow et al.   JAMA Cardiology

Economic Evaluation of PCSK9 Inhibitors in Reducing Cardiovascular Risk from Health System and Private Payer Perspectives

(2017) Alejandro Arrieta et al.   PLoS One

Cost-Effectiveness of LDL-C Lowering With Evolocumab in Patients With High Cardiovascular Risk in the United States

(2016) Shravanthi R. Gandra et al.   CLINICAL CARDIOLOGY

2016 ESC/EAS Guidelines for the Management of Dyslipidaemias

(2016) Alberico L. Catapano et al.   EUROPEAN HEART JOURNAL

Cost-effectiveness of PCSK9 Inhibitor Therapy in Patients With Heterozygous Familial Hypercholesterolemia or Atherosclerotic Cardiovascular Disease

(2016) Dhruv S. Kazi et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Country-Level Cost-Effectiveness Thresholds: Initial Estimates and the Need for Further Research

(2016) Beth Woods et al.   VALUE IN HEALTH

Methods for the estimation of the National Institute for Health and Care Excellence cost-effectiveness threshold

(2015) Karl Claxton et al.   HEALTH TECHNOLOGY ASSESSMENT

Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events

(2015) Jennifer G. Robinson et al.   NEW ENGLAND JOURNAL OF MEDICINE

Assessing the Value of New Treatments for Hepatitis C: Are International Decision Makers Getting this Right?

(2015) Beth Woods et al.   PHARMACOECONOMICS

Effect of Evolocumab or Ezetimibe Added to Moderate- or High-Intensity Statin Therapy on LDL-C Lowering in Patients With Hypercholesterolemia

(2014) Jennifer G. Robinson et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Economic Evaluation of Warfarin, Dabigatran, Rivaroxaban, and Apixaban for Stroke Prevention in Atrial Fibrillation

(2014) Torbjørn Wisløff et al.   PHARMACOECONOMICS

Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials

(2010)   LANCET